Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential

25 Oct 2018

Abstract excerpt

Nonsense mutations, resulting in a premature stop codon in the open reading frame of mRNAs are responsible for thousands of inherited diseases. Readthrough of premature stop codons by small molecule drugs has emerged as a promising therapeutic approach to treat disorders resulting from premature termination of translation. The aminoglycoside antibiotics are a class of molecule known to promote readthrough at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to RNA and protein synthesis mechanisms
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30359426
DOI: 10.1371/journal.pone.0206158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potentialPMID 30359426Read ↗

Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop MutationsSemantic proximity Read ↗

Small molecule Y-320 stimulates ribosome biogenesis, protein synthesis, and aminoglycoside-induced premature termination codon readthrough.Semantic proximity Read ↗

Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.Semantic proximity Read ↗

Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons.Semantic proximity Read ↗

Gentamicin B1 is not a minor gentamicin component with major nonsense mutation suppression activitySemantic proximity Read ↗

Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.Semantic proximity Read ↗

Novel small molecules potentiate premature termination codon readthrough by aminoglycosides.Semantic proximity Read ↗

Statistical Analysis of Readthrough Levels for Nonsense Mutations in Mammalian Cells Reveals a Major Determinant of Response to GentamicinSemantic proximity Read ↗

Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.Semantic proximity Read ↗

Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codonsSemantic proximity Read ↗

Suppression of aminoglycoside-induced premature termination codon readthrough by the TRP channel inhibitor AC1903Semantic proximity Read ↗

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.